Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Hepcludex Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C30954-A

    Hepcludex (bulevirtide-gmod) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C30954-A alerts

    Get alerted when Policy C30954-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage of Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis D virus infection and defines documentation, clinical eligibility, prescriber, dosing, administration, and continuation requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyHepcludex (bulevirtide-gmod) Coverage Criteria
    Policy CodePolicy C30954-A
    Change TypeNew coverage criteria
    Effective DateSep 24, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization and ensure Hepcludex is prescribed by or in consultation with a board-certified gastroenterologist, hepatologist, or infectious disease specialist for members age 18 or older.
    SourceLink
    POLICY UPDATE CHANGES

    The policy documents the creation of new Hepcludex coverage criteria in Q3 2026.

    12 monthsInitial authorization
    12 monthsContinuation authorization
    8.5 mg dailyDose
    18+Minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    85%
    Continuation adherence

    Coverage Criteria

    Initial Therapy

    Initial coverage requires all of the following criteria:

    Initial therapy criteria

    • Chronic HDV infection: The member has a documented diagnosis of hepatitis D virus (HDV) infection confirmed by a positive anti-HDV antibody test and detectable HDV RNA (HDV viral load) within the past 6 months.Detectable HDV RNA within the past 6 months

      Documentation required.

    • HBV and laboratory assessment

      • Positive hepatitis B surface antigen (e.g., HBsAg).
      • Elevated alanine transaminase (ALT) laboratory values within the past 12 months.Elevated ALT within the past 12 months

        See ALT criteria in Appendix 1.

    • Concurrent HBV management: A treatment plan for concurrent hepatitis B virus (HBV) management, such as entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide, is documented, or treatment is documented as not clinically indicated under current AASLD guidance.

      Documentation required.

    • Liver disease status

      • The member has no evidence of cirrhosis.
      • The member has no evidence of previous decompensated liver disease within the last 2 years or current decompensated liver disease.

        Decompensated liver disease includes ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.

    Continuation Therapy

    Continuation of therapy requires all of the following criteria, including at least one documented positive clinical response:

    Continuation therapy criteria

    • Adherence

      • Adherence to therapy is at least 85% as verified by the prescriber or the member's medication fill history.≥85% adherence
      • Adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.
    • Safety: The prescriber attests to, or a clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive clinical response

    Coverage excludes members with cirrhosis or current decompensated liver disease, as well as decompensated liver disease occurring within the previous 2 years. Decompensation includes ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.

    No compendial approved off-label uses of Hepcludex are listed under this policy.

    All other uses of Hepcludex (bulevirtide-gmod) are considered experimental or investigational and are reviewed under Molina’s Off-Label policy.

    If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, Hepcludex must be immediately discontinued and appropriate treatment initiated.

    Severe acute exacerbations of hepatitis D and hepatitis B may occur after Hepcludex is discontinued, particularly in members with cirrhosis, who may be at increased risk for severe flares or progression to hepatic decompensation. Closely monitor hepatic function with clinical and laboratory follow-up, including HBV DNA and HDV RNA viral loads, for at least 6 months after discontinuation; resumption of antiviral therapy may be warranted.

    Coding and Clinical Coding Details

    HCPCS CodeHCPCS
    NANA
    Detectable HDV RNA
    Required testHDV RNA (HDV viral load) must be detectable.
    TimingThe detectable result must be from within the past 6 months.
    DocumentationA positive anti-HDV antibody test and detectable HDV RNA must confirm the documented HDV infection.
    Elevated ALT
    Required laboratory findingElevated alanine transaminase (ALT) laboratory values are required.
    TimingThe ALT results must be from within the past 12 months.
    Interpretation

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization and Specialist Prescriber

    Submit the Hepcludex coverage request with complete clinical documentation and ensure the drug is prescribed by, or in consultation with, a board-certified gastroenterologist, hepatologist, or infectious disease specialist.

    • Consultation-based prescribing requires submission of the consultation notes with both the initial request and reauthorization requests.
    Documentation Required

    General Medical Necessity Documentation

    Molina may request additional documentation, including patient records, test results, and the credentials of the provider ordering or performing the service. Reimbursement may be denied when documentation does not support medical necessity, non-investigational use, benefit eligibility, or appropriate billing practices.

    • Provide complete medical rationale for any exception request.

    Policy Background

    Hepcludex (bulevirtide-gmod) is indicated for the treatment of chronic hepatitis D virus infection in adults without cirrhosis or with compensated cirrhosis.

    Definitions and Clinical Terms

    Alanine aminotransferase (ALT)
    Enzyme functionALT is a hepatocellular enzyme predominantly localized within hepatocytes.
    Normal ALTNormal ALT is ≤19 U/L in females and ≤30 U/L in males.
    Elevated ALTElevated ALT is ≥2 times the upper limit of normal.
    AASLD HBV antiviral management
    Recommended antiviralEntecavir is recommended for chronic hepatitis B.
    Alternative antiviralsTenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) are also recommended options.
    Treatment guidance

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy is covered when all clinical, laboratory, liver-status, and concurrent HBV-management requirements are met:

    Initial therapy criteria

    • Chronic HDV infection: The member has a documented diagnosis of hepatitis D virus (HDV) infection confirmed by a positive anti-HDV antibody test and detectable HDV RNA (HDV viral load) within the past 6 months.Detectable HDV RNA within the past 6 months

      Documentation required.

    • Laboratory confirmation

      • Positive hepatitis B surface antigen (e.g., HBsAg).
      • Elevated alanine transaminase (ALT) laboratory values within the past 12 months.

    Continuation Criteria

    Continuation Therapy

    Continuation requires all listed conditions and at least one documented positive clinical response:

    Continuation therapy

    • Adherence

      • Adherence is at least 85% as verified by the prescriber or member medication fill history.≥85% adherence
      • Adherence is below 85% because surgery or treatment of an infection caused temporary discontinuation.
    • No intolerable toxicity: The prescriber attests to, or a clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Clinical response

    Quantity and Dosing Limits

    Hepcludex (bulevirtide-gmod)
    MedicationHepcludex (bulevirtide-gmod).
    Dose8.5 mg.
    FrequencyOnce daily.

    Site of Care and Administration

    Billing Rule

    Use pharmacy benefit coverage and self-administration

    Injectable Hepcludex is recommended for pharmacy benefit coverage and patient self-administration.

    Policy Summary
    PayerMolina Healthcare
    PolicyHepcludex (bulevirtide-gmod) Coverage Criteria
    Policy CodePolicy C30954-A
    Change TypeNew coverage criteria
    Effective DateSep 24, 2026
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization and ensure Hepcludex is prescribed by or in consultation with a board-certified gastroenterologist, hepatologist, or infectious disease specialist for members age 18 or older.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical Coding DetailsProvider Actions and DocumentationPolicy BackgroundDefinitions and Clinical TermsInitial Therapy CriteriaContinuation CriteriaQuantity and Dosing LimitsSite of Care and Administration
    HDV RNA is undetectable.Undetectable HDV RNA
  1. HDV RNA has declined by at least 2 log10 IU/mL from baseline.≥2 log10 IU/mL decline from baseline
  2. ALT laboratory values have normalized.

    See ALT criteria in Appendix 1.

  3. Other markers of liver disease have improved.
  4. Liver disease status: The member has no evidence of cirrhosis or decompensated liver disease.

    Decompensated liver disease includes ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.

  5. See the policy's ALT thresholds for clinical assessment.
    Continuation adherence
    Minimum adherenceAt least 85% adherence to therapy.
    ExceptionAdherence below 85% is permitted when surgery or treatment of an infection caused temporary discontinuation.
    VerificationAdherence is verified by the prescriber or the member's medication fill history.
    HDV RNA response
    Required responseAt least one positive clinical response must be documented for continuation.
    HDV RNA suppressionHDV RNA is undetectable.
    HDV RNA declineHDV RNA declines by at least 2 log10 IU/mL from baseline.
    Normal ALT
    Female thresholdNormal ALT is ≤19 U/L in females.
    Male thresholdNormal ALT is ≤30 U/L in males.
    Clinical useALT normalization is one documented positive clinical response outcome for continuation therapy.
    Elevated ALT
    Elevated ALT thresholdElevated ALT is defined as ≥2 times the upper limit of normal (ULN).
    Laboratory assessmentALT values are interpreted in the context of the patient's overall clinical presentation, underlying liver disease, and other laboratory findings.
    Clinical significancePersistent elevations may indicate ongoing hepatic inflammation, hepatocellular injury, or disease progression.
    Normal ALT
    Female thresholdNormal ALT is ≤19 U/L in females.
    Male thresholdNormal ALT is ≤30 U/L in males.
    Response criterionNormalization of ALT laboratory values is a positive clinical response outcome for continuation therapy.
    Elevated ALT
    Elevated ALT thresholdElevated ALT is defined as ≥2 times the upper limit of normal (ULN).
    Immune-active hepatitis BTreatment indications include elevated ALT of ≥2× ULN with high HBV DNA.
    Clinical contextALT is used to assess disease activity and monitor response to treatment in chronic HDV infection.
    High HBV DNA in immune-active chronic hepatitis B
    HBeAg-positive thresholdHigh HBV DNA is >20,000 IU/mL when HBeAg-positive.
    HBeAg-negative thresholdHigh HBV DNA is >2,000 IU/mL when HBeAg-negative.
    Disease phaseThese thresholds apply to the immune-active phase of chronic hepatitis B.
    Pregnancy HBV DNA threshold
    PopulationPregnant individuals with HBV require tailored management.
    Viral-load thresholdThe specified HBV DNA threshold is >200,000 IU/mL.
    Clinical contextPregnancy is identified as a special population in chronic hepatitis B treatment indications.
  6. Ensure submitted records support that treatment is medically necessary and within the member’s benefits.
  7. Documentation Required

    HDV and Laboratory Confirmation

    Document chronic HDV infection and the required supporting laboratory findings before requesting coverage.

    • Positive anti-HDV antibody and detectable HDV RNA (HDV viral load) within the past 6 months.
    • Positive hepatitis B surface antigen, such as HBsAg.
    • Elevated ALT laboratory values within the past 12 months.
    Documentation Required

    Concurrent HBV Management

    Document the treatment plan for concurrent HBV management or explain why HBV treatment is not clinically indicated under current AASLD guidance.

    • Examples of HBV therapy include entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide.
    Documentation Required

    Continuation Documentation

    For continuation requests, document adherence, clinical response, and treatment safety, and confirm that the member remains free of cirrhosis and decompensated liver disease.

    • Adherence is at least 85% as verified by the prescriber or medication fill history, unless lower adherence resulted from surgery or infection treatment causing temporary discontinuation.
    • The prescriber attests, or clinical review confirms, no intolerable adverse effects or drug toxicity.
    • Document at least one positive response: undetectable HDV RNA; a decline of at least 2 log10 IU/mL from baseline; normalized ALT; or improvement in other liver-disease markers.
    Documentation Required

    Specialist Consultation Notes

    When Hepcludex is prescribed in consultation, submit the specialist consultation documentation with the initial request and every reauthorization request.

    • The consulting specialist must be a board-certified gastroenterologist, hepatologist, or infectious disease specialist.
    Documentation Required

    Member-Specific Dosing Information

    Include the member-specific measurement required to evaluate medical necessity whenever the requested drug dose depends on weight, body surface area, or another member-specific factor.

    • Provide the applicable measurement as part of the coverage review.
    Documentation Required

    Post-Discontinuation Monitoring

    If Hepcludex is discontinued, arrange clinical and laboratory follow-up for at least six months, particularly because patients with cirrhosis may be at increased risk for severe flares or hepatic decompensation.

    • Monitor hepatic function, HBV DNA, and HDV RNA viral load.
    • Consider whether resumption of antiviral therapy is warranted.
    Denial Risk

    Required Diagnostic Documentation Missing

    Missing required diagnostic or laboratory confirmation creates a denial risk. The initial request must establish chronic HDV infection with the specified antibody and RNA results and include the required HBV and ALT documentation.

    • Positive anti-HDV antibody and detectable HDV RNA must be documented within the past 6 months.
    • Positive HBsAg and elevated ALT within the past 12 months must also be documented.
    Denial Risk

    Cirrhosis or Decompensated Liver Disease

    Coverage may be denied when the member has cirrhosis or current or recent decompensated liver disease.

    • No evidence of cirrhosis is permitted.
    • No current or prior decompensated liver disease within the last 2 years, including ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.
    Denial Risk

    Continuation Criteria Not Met

    Continuation coverage is at risk when adherence, treatment response, or safety criteria are not met or cannot be documented.

    • Adherence must generally be at least 85%, subject to the stated exception for temporary discontinuation due to surgery or infection treatment.
    • Document a qualifying clinical response and absence of intolerable adverse effects or drug toxicity.
    • The member must continue to have no cirrhosis or decompensated liver disease.
    Denial Risk

    Age or Prescriber Requirement Not Met

    Hepcludex coverage is limited to members who are at least 18 years old and whose prescription is issued by or made in consultation with the required board-certified specialist.

    • Minimum age: 18 years.
    • Acceptable specialists are gastroenterologists, hepatologists, or infectious disease specialists who are board certified.
    • Consultation notes are required with initial requests and reauthorizations when prescribing is consultation-based.
    Denial Risk

    Noncovered or Investigational Use

    All other uses of Hepcludex are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • The policy lists no labeled contraindications, but noncovered uses remain subject to the Off-Label policy.
    Selection is guided by disease phase, viral load, ALT levels, fibrosis stage, and patient-specific factors.
    Alanine aminotransferase (ALT)
    Clinical roleALT is a hepatocellular enzyme and a sensitive marker of liver injury.
    Normal valuesFor clinical assessment, normal ALT is no more than 19 U/L in females and 30 U/L in males.
    Elevated valuesALT is elevated at ≥2 times the upper limit of normal; persistent elevations may indicate hepatic inflammation, injury, or disease progression.
    Chronic hepatitis D virus infection
    Antibody persistenceHDV antibodies persist for more than 6 months.
    Viral markerDetectable HDV RNA or hepatitis D antigen (HDAg) is present.
    DefinitionBoth persistent HDV antibodies and a detectable viral marker define chronic HDV infection.
    Hepcludex mechanism of action
    Drug classHepcludex is a viral entry inhibitor.
    TargetIt binds to sodium taurocholate co-transporting polypeptide (NTCP) surface receptors.
    EffectThis prevents entry of HDV and HBV into hepatocytes.
    Elevated ALT within the past 12 months

    See ALT criteria in Appendix 1.

  8. Concurrent HBV management: A treatment plan for concurrent hepatitis B virus (HBV) management, such as entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide, is documented, or treatment is documented as not clinically indicated under current AASLD guidance.

    Documentation required.

  9. Liver status

    • The member has no evidence of cirrhosis.
    • The member has no evidence of previous decompensated liver disease within the last 2 years or current decompensated liver disease.

      Decompensated liver disease includes ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.

    • HDV RNA is undetectable.Undetectable HDV RNA
    • HDV RNA has declined by at least 2 log10 IU/mL from baseline.≥2 log10 IU/mL decline from baseline
    • ALT laboratory values have normalized.

      See ALT criteria in Appendix 1.

    • Other markers of liver disease have improved.
  10. No cirrhosis or decompensation: The member has no evidence of cirrhosis or decompensated liver disease.

    Decompensated liver disease includes ascites, hepatic encephalopathy, variceal bleeding, or Child-Pugh class B or C.